scholarly journals UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)

ESMO Open ◽  
2019 ◽  
Vol 4 (5) ◽  
pp. e000562 ◽  
Author(s):  
Ines Vaz-Luis ◽  
Paul Cottu ◽  
Christel Mesleard ◽  
Anne Laure Martin ◽  
Agnes Dumas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Patient Reported Outcomes ◽  
Breast Conserving Surgery ◽  
Blood Collection ◽  
Long Term Effects ◽  
Adjuvant Trastuzumab ◽  
Patient Reported ◽  
Prospective Longitudinal

BackgroundCorresponding with improved survival among patients with breast cancer, the awareness of the long-term effects of cancer treatments has increased. CANcer TOxicities (CANTO) aims to identify predictors of development and persistence of long-term toxicities in patients treated for stages I–III breast cancer and to characterise their incidence, as well their impact. In this paper, we describe the methodology used in this study and provide a first characterisation of the study population.MethodsCANTO (NCT01993498) is a French prospective, longitudinal cohort study enrolling patients with invasive cT0-cT3cN0-3M0 breast cancer of 26 French cancer centres. Patients are assessed at diagnosis, 3–6 (M0), 12 (M12), 36 (M36) and 60 (M60) months after completion of primary surgery, chemotherapy or radiotherapy whichever comes last. CANTO collects clinical, treatment, toxicity data, an extensive list of validated patient-reported outcomes (focusing on quality of life, psychological and behavioural questionnaires) and ad hoc socioeconomic questionnaires. Blood collection is performed at diagnosis, M0, M12, M36 and M60. Biologic sub-studies are ongoing (eg, microbiotic and cognitive sub-study).ResultsEnrolment started in 2012; by October 2018, 12 012 patients had been enrolled. Data collected have a low missing completion rate (<5% for key clinical variables, <20% for patient-reported outcomes). Blood, serum and plasma samples are stored in over 96% of patients. Among the first 5801 patients enrolled in CANTO, 76.7% of patients had hormone receptor positive and human epidermal growth factor 2 negative tumours; 73.1% of patients had breast conserving surgery; 90.4% received adjuvant radiotherapy, 53.4% (neo) adjuvant chemotherapy, 11.3% adjuvant trastuzumab and 80.3% adjuvant hormonotherapy.ConclusionsCANTO represents a unique opportunity to explore important medical, biological and psychosocial outcomes on breast cancer survivor population.

Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes

2019 ◽  
Vol 17 (8) ◽  
pp. 1641-1642.e1 ◽  
Author(s):  
Zobair M. Younossi ◽  
Maria Stepanova ◽  
Issah Younossi ◽  
Calvin Q. Pan ◽  
Harry L.A. Janssen ◽  
...  
Keyword(s):  
Patient Reported Outcomes ◽  
Hbv Infection ◽  
Long Term Effects ◽  
Chronic Hbv Infection ◽  
Patient Reported ◽  
Chronic Hbv

UNICANCER: Prospective cohort study of treatment related chronic toxicities in patients with localized breast cancer (CANTO).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. TPS10125-TPS10125
Author(s):  
Ines Maria Vaz Duarte Luis ◽  
Paul H. Cottu ◽  
Christel Mesleard ◽  
Anne-Laure Martin ◽  
Agnes Dumas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Treatment Completion ◽  
Breast Cancer Patients ◽  
European Organization ◽  
Patient Reported

TPS10125 Background: Corresponding with improved survival among breast cancer patients an awareness of the long term effects of cancer treatments has increased. There is now a call for better coordination of care and management of these patients to focus on their survivorship. This study will identify factors associated with the development and persistence of long term toxicities in patients treated for Stage I-III breast cancer. In addition, it will characterize their incidence as well as, psychological, social and economic impacts. Methods: This is a prospective cohort study enrolling newly diagnosed invasive cT0-cT3, cN0-3, M0 breast cancer patients of 26 French comprehensive cancer centers. All patients will be followed for a minimum of 5 years. Patients will be assessed at diagnosis, 3-6 (M0), 12 (M12), 36 (M36), 48 (M48), 60 (M60), months after treatment completion. Treatment completion is defined as completion of primary surgery, chemotherapy or radiotherapy, whichever comes last. Adjuvant trastuzumab, endocrine therapy or participation in clinical trials can be ongoing. CANTO collects an extensive list of clinical, treatment, and toxicity data including validated patient reported outcomes questionnaires ( Hospital Anxiety and Depression scale [HADS], Scheier et Carver’s Questionnaire, Life Orientation Test-Revised [LOT-R], Beck Depression Inventory [BDI-SF], European Organization for Research and Treatment-QOL questionnaire for breast cancer [EORTC QLQC30-BR23], EORTC-FA13, 12 Item Short Form Survey [SF12], Global physical activity questionnaire [GPAQ]6, impact of cancer questionnaire [IOCv2], economic and social questionnaires). Blood collection is available for all patients at diagnosis, M0, M12, M36 and M60. Genotyping will be performed in all samples. Biologic substudies are ongoing (e.g, microbiotic and cognitive substudy). CANTO aggregates a multidisciplinary team of French investigators and created a dedicated national network. Enrolment started in 2012 and by December 2016, 10030 patients were already enrolled, with a goal of 12.000 patients. Clinical trial information: NCT01993498.

Sign in / Sign up

Export Citation Format

Share Document